Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEPAC-TDM paclitaxel pharmacokinetic-guided dosing in advanced NSCLC
2010-023688-16Phase 3Completed
- Sponsor
- Central European Society for Anticancer Drug Research
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Central European Society for Anticancer Drug Research. Primary endpoint: Frequency of grade 4 neutropenia during cycle 2. Started Jan 2011; status: completed.
02
Drugs
paclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2010-023688-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023688-16.